3-oxo-4-[2-(4-{[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]-oxazin-6-yl)methyl]amino}piperidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 3-oxo-4-[2-(4-{[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]-oxazin-6-yl)methyl]amino}piperidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carbonitrile
• 英文别名: 3-oxo-4-[2-(4-([(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino)piperidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carbonitrile；3-Oxo-4-[2-(4-{[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino}piperidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carbonitrile；3-oxo-4-[2-[4-[(3-oxo-4H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino]piperidin-1-yl]ethyl]-1,4-benzoxazine-6-carbonitrile
• 化学式: C₂₄H₂₆N₆O₄
• 分子量: 462.508
• InChiKey: ILRMRAZASPTXGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-oxo-4-[2-(4-{[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]-oxazin-6-yl)methyl]amino}piperidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carbonitrile 在 sodium azide 、 三乙胺盐酸盐 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成
  参考文献：
  名称：

  Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors

  摘要：

  An SAR survey at the C-6 benzoxazinone position of a novel scaffold which inhibits bacterial type IIa topoisomerase demonstrates that a range of small electron donating groups (EDG) and electron withdrawing groups (EWG) are tolerated for antibacterial activity. Cyano was identified as a preferred substituent that affords good antibacterial potency while minimizing hERG cardiac channel activity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.126
• 作为产物：
  描述：

  3-氧代-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-甲腈 在 sodium hydride 、 sodium cyanoborohydride 、 三氟乙酸 作用下， 以 甲醇 、 氯仿 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-oxo-4-[2-(4-{[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]-oxazin-6-yl)methyl]amino}piperidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carbonitrile
  参考文献：
  名称：

  Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors

  摘要：

  An SAR survey at the C-6 benzoxazinone position of a novel scaffold which inhibits bacterial type IIa topoisomerase demonstrates that a range of small electron donating groups (EDG) and electron withdrawing groups (EWG) are tolerated for antibacterial activity. Cyano was identified as a preferred substituent that affords good antibacterial potency while minimizing hERG cardiac channel activity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.126

文献信息

• Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity
  作者：Folkert Reck、Richard Alm、Patrick Brassil、Joseph Newman、Boudewijn DeJonge、Charles J. Eyermann、Gloria Breault、John Breen、Janelle Comita-Prevoir、Mark Cronin、Hajnalka Davis、David Ehmann、Vincent Galullo、Bolin Geng、Tyler Grebe、Marshall Morningstar、Phil Walker、Barry Hayter、Stewart Fisher

  DOI：10.1021/jm2008826

  日期：2011.11.24

  isolates, but suffer from potent hERG inhibition (IC50= 3 μM for 1). We now disclose the finding that new analogues of 1 with an N-linked cyclic amide moiety attached to the ethyl bridge, such as 24m, retain the broad-spectrum antibacterial activity of 1 but show significantly less hERG inhibition (IC50= 31 μM for 24m) and higher free fraction than 1. One optimized analogue, compound 24l, showed moderate

  新型的细菌II型拓扑异构酶的非氟喹诺酮抑制剂（DNA促旋酶和拓扑异构酶IV）对于开发不受靶标介导的氟喹诺酮类交叉耐药性影响的新型抗菌剂具有重要意义。具有通过碳与乙基桥连接的双环芳族部分的氨基哌啶，例如1，通常显示出强效的广谱抗菌活性，包括对喹诺酮类耐药的菌株，但受到强的hERG抑制作用（IC 50 = 3μM/ 1） 。我们现在公开的发现是，新的1的类似物具有连接到乙基桥的N-连接的环状酰胺部分，例如24m，保留了其的广谱抗菌活性。1，但显示出显着更少的hERG抑制作用（24 m时IC 50 = 31μM）和高于1的游离分数。一种优化的类似物化合物24l在狗的大腿感染模型中在狗中表现出中等清除率，并且有望抵抗金黄色葡萄球菌。
• Compounds for the treatment of multi-drug resistant bacterial infections
  申请人：AstraZeneca AB

  公开号：US07875715B2

  公开（公告）日：2011-01-25

  The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

  本发明涉及表现出抗菌活性的化合物，其制备过程，含有其作为活性成分的药物组合物，以及它们作为药物的使用和用于制造用于治疗温血动物（如人类）细菌感染的药物的使用。特别地，本发明涉及用于治疗温血动物（如人类）细菌感染的有用化合物，更具体地涉及这些化合物用于制造用于治疗温血动物（如人类）细菌感染的药物。
• COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS
  申请人：Breault Gloria

  公开号：US20110092495A1

  公开（公告）日：2011-04-21

  The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

  本发明涉及表现出抗菌活性的化合物，其制备过程，含有它们作为活性成分的制药组合物，它们作为药物的使用以及它们在制造用于治疗温血动物（如人类）细菌感染的药物中的使用。特别是本发明涉及用于治疗温血动物（如人类）细菌感染的有用化合物，更具体地涉及这些化合物在制造用于治疗温血动物（如人类）细菌感染的药物中的使用。
• US7875715B2
  申请人：——

  公开号：US7875715B2

  公开（公告）日：2011-01-25
• US8124602B2
  申请人：——

  公开号：US8124602B2

  公开（公告）日：2012-02-28